肺炎链球菌融合蛋白疫苗研究进展  

Research Progress in Streptococcus Pneumoniae Fusion Protein Vaccine

作　　者：张素婷 黄健 闵迅 ZHANG Suting;HUANG Jian;MIN Xun(School of Laboratory Medicine,Zunyi Medical University,Zunyi 563006,China;Department of Medical Laboratory,Affiliated Hospital of Zunyi Medical University,Zunyi 563003,China)

机构地区：[1]遵义医科大学检验医学院,贵州遵义563006 [2]遵义医科大学附属医院医学检验科,贵州遵义563003

出　　处：《医学综述》2019年第14期2772-2777,共6页Medical Recapitulate

基　　金：国家自然科学基金(81460317);贵州省科学技术基金(黔科合LH字[2014]7553号)

摘　　要：肺炎链球菌是一种对人类健康危害较大的条件致病菌,目前其疫苗研究已取得了巨大突破,但既往研究主要集中在荚膜多糖疫苗上,存在诸多局限性。近年来,随着生物学技术及基因工程技术的飞速发展,由肺炎链球菌毒力因子及表面蛋白制作的蛋白疫苗研发迅速。其中,将肺炎链球菌不同的表面蛋白质作为免疫原组分构建的融合蛋白疫苗,极大地增强了疫苗的免疫原性,且已取得一定的试验效果,未来进一步研究将有望取代荚膜多糖疫苗。Streptococcus pneumoniae is a kind of conditional pathogen which is harmful to human health.At present,great breakthroughs have been made in the vaccine research.However,previous studies mainly focused on capsular polysaccharide vaccine,which has many limitations.In recent years,with the rapid development of biological technology and gene engineering technology,protein vaccines made from virulence factors and surface proteins of streptococcus pneumoniae are in rapid development.Among them,the fusion protein vaccine constructed with different surface proteins of streptococcus pneumoniae as immunogenic components has greatly enhanced the immunogenicity of the vaccine,and has achieved certain test results,which may hopefully replace the capsular polysaccharide vaccine with further studies in the future.

关 键 词：肺炎链球菌 融合蛋白疫苗 肺炎链球菌表面蛋白 肺炎链球菌溶血素 肺炎链球菌表面黏附素A 

分 类 号：R387.12[医药卫生—医学寄生虫学]